Introduction
============

Intratumoral heterogeneity refers to a mixture of phenotypically, functionally, and genetically different cancer cells with various cellular hierarchies or differentiation statuses within a tumor [@B1]. It is a common feature of almost all cancer types [@B1]. Tumor cell heterogeneity has been considered to be the major obstacle for effective cancer therapy, as heterogeneous cancer cells differ in their sensitivity to cancer therapy [@B2]. To date, studies have focused on genetic alterations as an underlying mechanism for the generation and maintenance of the tumor cell heterogeneity [@B3]. However, an increasing body of evidence supports the role of epigenetic modifications in the emergence of tumor heterogeneity. The formation of considerably heterogenetic spheres *in vitro* from a single cell, altered gene expression without genetic changes in many cancers, and the reversible changes in acquired drug resistance support epigenetic involvement in tumor heterogeneity [@B4], [@B5]. Nevertheless, limited information is available about the function of epigenetic modifications in intratumoral heterogeneity.

Epigenetic modifications are heritable and stable alterations of genes that do not change the DNA sequence and include DNA methylation, histone modification, and non-coding RNA interference [@B6]. DNA methylation has been extensively investigated regarding cancer development and progression [@B7]. While hypermethylation in the promoter of the cancer-related genes induces the silencing or down-regulation of tumor suppressor genes or DNA repair genes, global DNA hypomethylation drives oncogene activation and genomic instability [@B8]. Emerging evidence has suggested that aberrant DNA methylation may play a critical role in the generation of cancer cell heterogeneity [@B4]. Recent studies illustrated that epigenetic alterations, including aberrant DNA methylation, promote the heterogeneity of cancer stem cells (CSCs), preceding and/or predisposing to genetic changes [@B5], [@B9], [@B10].

Methylated DNA immunoprecipitation-based high throughput sequencing technology (MeDIP-seq) is the next generation sequencing (NGS) approach to analyze the DNA methylome [@B11]. MeDIP-seq is a useful tool for the rapid and efficient genome-wide assessment of DNA methylation in cancer epigenetics [@B11], [@B12]. For transcriptomic profiling, RNA-seq has been increasingly adopted to investigate the transcription profile in cells, tissues, and organisms because of its higher resolution relative to microarray-based methodology [@B13]. An integrated analysis of gene expression data with epigenetic profiling could be an effective approach to uncover the role of epigenetic modifications in cancer development and progression.

Human malignant mesothelioma (HMM) is an invariably fatal tumor arising from serosal surfaces of body cavities [@B14]. Many factors, including asbestos fibers and simian virus 40, are known to be closely associated with HMM tumorigenesis [@B15]. The annual incidence of HMM is relatively low, estimated to range from 0.6 to 30/1,000,000, but the global occurrence is expected to increase continuously in the coming decades [@B16]. HMM is extremely heterogeneous in its morphology and molecular phenotypes [@B17]. Using side population (SP) assays based on fluorescence-activated cell sorting (FACS), it has been shown that the SP fraction is enriched for more aggressive cells in HMM cell lines [@B18]. The prognosis of HMM is generally poor, with a median survival of 12 months from the diagnosis [@B19]. Despite progress in the understanding of its molecular carcinogenesis, the mechanisms underlying the resistance of HMMs to anticancer therapy remain unclear.

The present study was carried out to elucidate the molecular mechanism involved in the tumor cell heterogeneity using genome-wide analysis of SP and NSP cells isolated from a HMM cell line. Integrated analysis of the data from the MeDIP-seq and RNA-seq revealed that epigenetically regulated genes defined cancer cell subpopulations and their biological characteristics. To the best of our knowledge, this is the first genome-wide analysis of DNA methylation and transcriptomes in HMM cell subpopulations that sought to elucidate the molecular mechanisms underlying the development of intratumoral heterogeneity.

Materials and methods
=====================

Cell line and culture
---------------------

A HMM cell line, MS-1, was kindly provided by Dr. Jablons (University of California San Francisco, USA). The cell line was cultured in RPMI 1640 medium (Mediatech Inc., Manassas, VA, USA) supplemented with 10% fetal bovine serum (FBS; Mediatech Inc.), 10 mM HEPES (Sigma-Aldrich, St. Louis, MO, USA), 1.5 g/L sodium bicarbonate (Sigma-Aldrich), 1 mM sodium pyruvate (Sigma-Aldrich), and 100 U/100 μg/mL penicillin/streptomycin (Gibco-Life Technology, Gaithersburg, MD, USA) at 37^◦^C in a humidified atmosphere containing 5% CO~2~.

SP analysis
-----------

Cancer cell subpopulations were analyzed and isolated using an SP assay composed of Hoechst 33342 dye staining and subsequent flow cytometric analysis as described by Kai et al. [@B18]. Briefly, cultured cells were washed with phosphate-buffered saline (PBS), trypsinized and resuspended at 10^6^cells/mL in pre-warmed RPMI containing 2% FBS and 10 mM HEPES. The cells were incubated with Hoechst 33342 dye (5 μg/mL final concentration; Sigma-Aldrich, St. Louis, MO, USA) for 90 min at 37^◦^C with intermittent mixing. At the end of incubation, cells were spun down at 480 × g for 5 min and washed in cold PBS containing 2% FBS at 4^◦^C. Hoechst 33342 staining was detected using a flow cytometer sorter (Becton-Dickinson FACS Aria III, Becton-Dickinson, San Jose, CA, USA), exciting at 355 nm and detecting Hoechst Blue with a 450/50 broad pass filter and Hoechst Red with a 675/30 broad pass filter. At least 50,000 events within the live gate were examined to define an SP region, and an SP gate was identified using 50 μM verapamil hydrochloride, which blocks Hoechst 33342 dye efflux. SP and NSP cells were collected by a flow cytometry assisted cell sorter (FACS) based on the intensities of fluorescence and subjected to further analyses.

DNA preparation, library construction and MeDIP-seq
---------------------------------------------------

The DNA library was constructed as described [@B20]. Briefly, genomic DNAs were extracted from the sorted SP and NSP cells by an Exgene Genomic DNA Micro Kit (GeneAll Biotechnology Co. Ltd., Seoul, The Republic of Korea) according to the manufacturer\'s recommendations. The concentration and purity of the DNA were measured using Nanodrop (Nanodrop Technologies, Wilmington, DE, USA). The high quality of total DNA was subjected to MeDIP-seq analysis performed at Theragen Bio Institute (Suwon-city, Gyeonggi-do, The Republic of Korea). The qualified library was directly sequenced using an Illumina HiSeq 2000 sequencer (Illumina Inc, San Diego, CA, USA) according to the manufacturer\'s protocol.

Identification of differential DNA methylation regions (DMRs)
-------------------------------------------------------------

Detailed analysis of the MeDIP-seq data was performed as described [@B20]. Briefly, the high quality of clean reads was mapped to a human reference genome (hg19) using an alignment program, the Short Oligonucleotide Analysis Package software (SOAP, <http://soap.genomics.org.cn>). Whole genome peak scanning was performed using the Model-based Analysis of ChIP-seq (MACS: Software version-1.4.0). Dynamic Poisson distribution was used to calculate the p-value of a specific region based on the number of unique mapped reads. The region with a p-value of less than 10e-5 was defined as a peak. The distribution of peaks was analyzed in the upstream 2k, 5\' UTR, exon, intron, 3\' UTR, downstream 2k, and repeat element regions and in each class of repetitive elements. CpG islands and the gene body were divided into 40 equal regions. The upstream and downstream 2 kb regions were divided into 20 equal regions. For each region, the normalized number of reads was calculated. Peaks of MeDIP-seq data from SP and NSP cells were merged to find candidate DMRs. Then, numbers of the reads were assessed by chi-square statistics and false discovery rate statistics to obtain true DMRs. The p-value of the filtering standard was 0.05, and a 2-fold change in the difference of read numbers was used as a criterion for the DMRs. The methylation status of the NSP sample was utilized as a reference for the up- or down-regulation of DNA methylation in the SP fraction.

MeDIP-seq data validation by bisulfite sequencing
-------------------------------------------------

To verify differentially methylated genes between SP and NSP cells, 500 ng of genomic DNA from each SP and NSP sample was treated with sodium bisulfite using the EZ DNA Methylation-Gold kit (Zymo Research, Orange, CA, USA). Methylated and unmethylated primer sets were designed in MethyPrimer-Design (<http://www.urogene.org/methprimer>). Primer sequences for the genes selected for validation are documented in Table [S3](#SM0){ref-type="supplementary-material"}.

RNA isolation and RNA-seq
-------------------------

The RNA library was constructed as described [@B21]. Briefly, total RNAs from the sorted SP and NSP cells were isolated using a phenol-chloroform method with Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer\'s instructions. The quality and quantity of the total RNAs were determined using Nanodrop (Nanodrop Technologies). Total RNAs with high quality were subjected to NGS assay performed at the DNA Link Incorporation (Songpa-gu, Seoul, The Republic of Korea). Sequencing libraries of mRNAs were prepared using an Illumina TruSeq RNA Prep kit v2 (Illumina Inc.) according to the manufacturer\'s instructions. The quality of the amplified libraries was verified using an Agilent Technologies 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). Cluster generation was carried out in the flow cells on the cBot automated cluster generation system (Illumina Inc.), and then the flow cells were loaded on a HiSeq 2000 sequencing system (Illumina Inc.) with 200 bps paired-end reads.

Identification of differentially expressed genes (DEGs)
-------------------------------------------------------

Detailed analysis of the RNA-seq data was performed as described [@B21]. Briefly, the high quality of clean reads was mapped to the hg19 with TopHat (ver. 2.0.9). The Bam file was used as the output to store a list of read alignments and was added to the Cufflinks software package (ver. 2.0.2) to predict transcript structures and compare transcriptome profiles based on the RNA-Seq data [@B22]. To compare the expression level of a gene across samples, read counts obtained from RNA-seq were normalized as fragments per kilobase of transcript per million mapped fragments (FPKM) [@B23]. The FPKM was used to identify DEGs in SP and NSP subpopulations, and then the FPKM in each sample was compared and transformed to the Log~2~ratio (log~2~(number of SP reads) - log~2~(number of NSP reads)). The gene expression of the NSP subpopulation was used as control data for the up- or down-regulation of gene expression in SP cells. Genes with a p-value of \< 0.05 and a log2-transformed value smaller than -1 or greater than 1 were considered to be statistically significant DEGs.

Validation of RNA-seq data by quantitative real-time RT-PCR
-----------------------------------------------------------

The total RNA 400 ng was used to synthesize cDNA using QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA, USA). Quantitative real-time PCR was performed using the Rotor-Gene SYBR Green RT-PCR Kit (Qiagen). The PCR conditions were as follows: 95^◦^C for 5 min followed by 45 cycles of 95^◦^C for 10 seconds and ending at 60^◦^C for 30 seconds. Expression levels of each target gene were normalized to the endogenous GAPDH level. The relative gene expression was analyzed as described [@B24]. Primer sequences for the target genes selected for validation are documented in Table [S4](#SM0){ref-type="supplementary-material"}.

Integrated analysis of DMGs and DEGs
------------------------------------

MeDIP-seq and RNA-seq data were interpreted in an integrated way to identify epigenetically regulated genes that define SP subpopulations. DEGs that retain DMRs in the regulatory areas were selected as candidate genes. A fold change \> 2 and p-value \< 0.05 were used as filtering criteria. DEGs containing both differentially hypermethylated and hypomethylated genomic regions were excluded from the candidates. To investigate whether the epigenetically regulated DEGs have CpG islands, the genome browser embedded in the UCSC Genome Bioinformatics software (Santa Cruz, CA, USA; <http://genome.ucsc.edu/cgi-bin/hgGateway>) was performed using a WIG file of MeDIP-seq signals. All analyses were based on hg18.

Gene ontology (GO) analysis
---------------------------

To determine the key regulatory components and functional relationships of genes, gene products or gene-product groups from the high-throughput sequencing data, GO analysis was performed [@B25]. The web-based software toolkit for gene ontology enrichment analysis (GOEAST, <http://omicslab.genetics.ac.cn/GOEAST>) was used to visualize the biological process, molecular function, and cellular component terms for the target genes. Using the MeDIP-integrated RNA-seq data, GO enrichment revealed the biological implications of the list of genes showing epigenetically concomitant changes in aberrant DNA methylation and gene expression. GO terms with a fold change \> 2 and p-value of less than 0.05 were considered functionally relevant.

Results
=======

Isolation of DNA and RNA from the subpopulations of HMM cells
-------------------------------------------------------------

MS1 cells were subjected to SP analysis, which consisted of Hoechst 33342 dye staining and subsequent flow cytometry. A small subset of SP cells, ranging from 0.2% to 3.2% of the total cells, was identified in the MS1 cells as a distinct tail in the flow cytometry plot (Figure [1](#F1){ref-type="fig"}A). The SP fraction was decreased by treatment with 50 μM verapamil hydrochloride (Figure [1](#F1){ref-type="fig"}B). The quality of RNA samples from the sorted SP and NSP cells of MS1 cells was assessed by gel electrophoresis and absorbance at a A260/280 ratio by Agilent\'s 2100 Bioanalyzer and Nanodrop. RNAs with a A260/280 ratio greater than 1.8 and an RNA Integrity Number (RIN) value greater than 8 were subjected to the further analysis.

Global mapping of DNA methylation
---------------------------------

After data cleaning as described in the Materials and Methods section, a total of 48,979,592 reads were obtained by MeDIP-seq analysis of the SP and NSP cells. Approximately 92% of the total reads from each sample were aligned to the reference genome, and consequently, 68.26% and 71.90% of the reads from the SP and NSP samples were mapped to the human genome, respectively (Table [S1](#SM0){ref-type="supplementary-material"}). The MeDIP-seq reads were distributed across most human chromosomes with variable densities (Figure [2](#F2){ref-type="fig"}A). Most reads in both samples were concentrated in the repeat and intron regions, and a relatively small portion of reads was allocated to the other genomic elements (Figure [2](#F2){ref-type="fig"}B). The distribution of MeDIP-seq reads around CpG islands was further investigated because aberrant DNA methylation in CpG islands has been known to induce changes in gene expression more than other genomic regions. The levels of DNA methylation in the CpG islands and in the upstream 2 kb and downstream 2 kb regions of the CpG islands were significantly higher in SP cells than in NSP cells. The DNA methylation level of SP cells was progressively increased in the upstream 2k regions, markedly decreased at the beginning of the CpG islands, and dramatically increased at the end of the CpG islands (Figure [2](#F2){ref-type="fig"}C). On the other hand, the methylation level around the gene body was generally higher in SP cells than in NSP cells (Figure [2](#F2){ref-type="fig"}D).

MACS, a peak scanning software, revealed 194,781 peaks and 177,650 peaks in SP and NSP cells, respectively, accounting for approximately 6% of the peak coverage rate in the whole genome (Table [S2](#SM0){ref-type="supplementary-material"}). By merging the peaks of methylation, 18,154 differentially hypermethylated peaks and 8,577 differentially hypomethylated peaks were identified with various genomic contexts in SP cells compared to NSP cells. Distribution of the peaks was analyzed in upstream 2k, 5\' UTR, exon, intron, 3\' UTR and downstream 2k regions. A large proportion of peaks were found in the intron region, followed by CDS, upstream 2k, downstream 2k, 3\' UTR, and 5\' UTR in SP and NSP cells (Figure [S1](#SM0){ref-type="supplementary-material"}). To evaluate the general methylation level of each gene element, the coverage of peaks that equaled the length of the peak occupying region divided by the total length of the corresponding element was measured. In contrast to the distribution of peak reads, the peak coverage of introns was the lowest among other genomic elements (Figure [S1](#SM0){ref-type="supplementary-material"}).

Differentially methylated genes (DMGs) and the validation of MeDIP-seq data using bisulfite sequencing
------------------------------------------------------------------------------------------------------

The distribution of differentially methylated genes between SP and NSP cells in different genomic contexts was determined (Table [S5](#SM0){ref-type="supplementary-material"}). A total of 6,400 genes were differentially hypermethylated, and 3,483 genes were differentially hypomethylated in SP cells compared to NSP cells, containing a total of 2,161 DMGs of simultaneous hypermethylated and hypomethylated regions. The sequencing data of the methylome in the present study are available in the National Center for Biotechnology Information Sequence Read Archive (<http://www.ncbi.nlm.nih.gov/Traces/sra>/) under accession numbers SRR2062225 and SRR2062224.

To validate the MeDIP-seq data, methylation-specific PCR (MSP) was performed for 4 selected DMGs: ATPase, Class VI, Type 11 (ATP11A), zinc finger, DHHC-type containing 20 (ZDHHC20), twisted gastrulation BMP signaling modulator 1 (TWSG1), and secreted frizzled-related protein 1 (SFRP1) (Figure [3](#F3){ref-type="fig"}). MSP results confirmed the data from the MeDIP-seq analysis.

Mapping of the RNA-seq library sequencing data
----------------------------------------------

After removing poor quality sequences during the quality control steps, approximately 85 million clean reads were generated from SP and NSP samples and subsequently mapped to the hg18 using a TopHat aligner. A total of 73,888,650 and 72,799,414 RNA-seq reads were mapped to the hg18, with 96.32% and 96.10% of the mapping rate in SP and NSP samples, respectively (Table [S6](#SM0){ref-type="supplementary-material"}). The quality score across all bases represented high accuracy based on the base-calling process using Illumina pipeline software.

Identification of DEGs and the validation of RNA-seq data using quantitative real-time RT-PCR
---------------------------------------------------------------------------------------------

Differentially expressed genes (DEGs) were analyzed from the Bam file, a standard file of the resulting read alignments. The Cuffdiff program was employed to find potential genes that showed significant differences in expression levels. Among the total genes and transcripts, Cuffdiff filtered a small portion of inadequate reads, including too complex or shallowly sequenced alignments and too short or too numerous fragments in the locus. By comparing the RNA-seq data of SP and NSP, the differential expression of 1,130 genes from a total of 17,122 mRNAs was identified. Among these genes, 795 DEGs were significantly up-regulated and 335 DEGs were down-regulated in the SP cells compared to the NSP cells. The sequencing data of the transcriptome in the present study are available in the National Center for Biotechnology Information Sequence Read Archive (<http://www.ncbi.nlm.nih.gov/Traces/sra>/) under accession number SRR2062223 and SRR2064655.

To validate the expression level of differentially regulated genes in RNA-seq data, real-time RT-PCR was performed for 6 selected DEGs: immediate early response 3 (IER3), argininosuccinate synthase 1 (ASS1), dual specificity phosphatase 15 (DUSP15), slit homolog 2-(Drosophila) (SLIT2), protein tyrosine phosphatase, non-receptor type 13 (PTPN13), and FAT atypical cadherin 1 (FAT1). The RT-PCR results were generally concordant with RNA-seq data, although there was a small difference in the degree of fold changes (Figure [4](#F4){ref-type="fig"}A and 4B).

Integrated analysis of DMGs and DEGs
------------------------------------

Data from MeDIP-seq and RNA-seq were analyzed in an integrated manner to identify a subset of genes that were regulated by DNA methylation. The comprehensive distribution pattern of the genes with both differential methylation and expression levels were illustrated (Figure [5](#F5){ref-type="fig"}A). After merging overlapping DMGs containing DMRs with different gene elements into the unitary DMG, a total of 7722 DMGs, including 2,161 simultaneously hypermethylated and hypomethylated DMGs, were identified. Among the many unique DMGs, 512 DMGs with 89 up-regulated and 423 down-regulated genes were found to be significantly regulated in SP cells compared to NSP cells. Their bidirectional gene expression patterns were located in the various genomic regions (Figure [5](#F5){ref-type="fig"}B and 5C). The DMGs showing the opposite expression relative to their corresponding methylation status or simultaneously containing at least two regions of differential hypermethylation and hypomethylation were excluded from the subsequent integrated analysis. Consequently, a total of 122 DEGs were considered as potential candidate genes regulated by aberrant DNA methylation, including 118 hypermethylated genes showing simultaneous down-expression and 4 hypomethylated genes showing concurrent up-expression (Table [S7](#SM0){ref-type="supplementary-material"}). Among those genes, DMGs containing methylated sequences in the upstream 2k region were further investigated using the UCSC genome browser to determine whether differentially methylated sequences included CpG islands. This analysis revealed that a total of 10 DMGs exhibited altered methylation in CpG islands (Table [1](#T1){ref-type="table"} and Figure [S2](#SM0){ref-type="supplementary-material"})*.* In particular, TWSG1, BNC1, RPS6KA3 and DUSP15 exhibited differential methylation in the CpG islands of the promoter region.

GO analysis of the epigenetically regulated DEGs
------------------------------------------------

To determine biologically functional relationships among epigenetically regulated DEGs, GO analysis was performed. A total of 122 DEGs, including 118 down-regulated genes with hypermethylation and 4 up-regulated genes with hypomethylation, were subjected to GO analysis. In total, 102 GO terms were enriched in the integrated epigenome data, including 7 enriched GO terms under the cellular component category, 46 enriched GO terms under the molecular function category, and 49 enriched GO terms under the biological process category. Statistically significant profiles of GO terms with a p-value less than 0.05 in the 3 categories were determined (Table [S8](#SM0){ref-type="supplementary-material"}). It was noteworthy that the 3 most significantly enriched GO terms in the biological process were stem cell maintenance, stem cell development, and stem cell differentiation. GO terms could not be acquired for hypomethylated DEGs due to the insufficient number of the submitted genes.

Discussion
==========

In the present study, integrated analysis of MeDIP-seq and RNA-seq data from distinct cancer cell subpopulations in a HMM cell line revealed a set of 122 differentially regulated genes, including 118 down-regulated genes with hypermethylation and 4 up-regulated genes with hypomethylation. The results indicated that genes defining the subpopulations of HMM cells could be regulated epigenetically. Although the use of additional HMM cell lines or human disease samples would solidify the conclusion, the data obtained from the present study clarify clearly suggests that DNA methylation may play a pivotal role in the genesis of intratumoral heterogeneity, possibly by regulating the more aggressive properties of CSCs.

Clonal evolution from a single cancer cell through genetic alterations has been conceptually believed to be a driving force for intratumoral heterogeneity, providing new properties favorable for survival and expansion [@B3]. However, emerging evidence suggests that tumor heterogeneity arises from epigenetic modifications of tumor cells independent of genetic mutations [@B4], [@B5], [@B26]. In a support of this notion, Feinberg and colleagues [@B5] demonstrated that epigenetic alterations in cancer progenitor cells drive intratumoral heterogeneity during the exacerbation of tumor progression. In solid tumors, CSCs exhibited more heterogeneous patterns of DNA methylation than their differentiated progeny and contributed to the generation of population heterogeneity [@B27]. It is evident that the dysregulation of DNA methylation as an early molecular event promotes the expression of malignant phenotypes in cancers [@B28].

HMM was selected as a paradigmatic model for the present study about intratumoral heterogeneity because HMM is extremely heterogeneous with regard to tumor cell morphology and molecular phenotypes [@B17] and contains distinct cancer cell subpopulations [@B18], [@B29]. HMM harbors fewer mutations than other cancers [@B30]. This feature is quite advantageous for the study of the potential involvement of non-genetic mechanisms relative to genetic alterations in the tumor heterogeneity of HMM.

Altered gene expression has been extensively investigated in HMM, and epigenetic deregulation leading to changes in the gene expression has been a constant finding in HMMs [@B31]. Altered DNA methylation, which is one of the most extensively studied epigenetic modifications, has been reported to play a key role in HMM tumorigenesis and the acquisition of malignant potentials during mesothelial transformation [@B28], [@B30]. Methylated CpG islands have been shown to affect a wide range of oncogenic processes in HMM, including uncontrolled cell proliferation, differentiation, apoptosis, and invasion. For example, asbestos fibers increase the prevalence of aberrant promoter methylation in the cell cycle control genes *APC* and *RASSF1* [@B32], [@B33]. The survival of HMM cells has been attributed to promoter methylation and the silencing of genes, including *SFRP4*, *SFRP5*, *FHIT*, and *SLC6A20* [@B30]. In cancers such as HMM, tumor heterogeneity is mainly controlled by the differentiation status of the tumor cells, which depends on the balance between self-renewal and the differentiation of tumorigenic CSCs into their progeny cells [@B9], [@B17]. Additionally, it is evident that DNA methylation is required for the maintenance of CSCs [@B34]. Thus, it is conceivable that deregulated DNA methylation not only confers CSCs better properties among heterogeneous populations but also facilitates the genesis of intratumoral heterogeneity. In the present study, epigenetically regulated genes are mainly attributed to the biological processes of not only stem cell maintenance, development, and differentiation (NOTCH2, STAG2, YAP1, and ZCCHC11) but also the negative regulation of differentiation and developmental processes (ROCK1, ROCK2, GTF2I, ITGB3, MED1, NOTCH2, PKP2, STAG2, THBS1, TWSG1, YAP1, ZCCHC11). The GO terms enriched for the candidate genes indicate that putative CSCs regulate stem cell properties epigenetically by modulating the DNA methylation status and, at least in part, by regulating the potency of differentiation. Of the aberrantly methylated genes, YAP1 (yes-associated protein 1) was shown to play a pivotal role in the differentiation of stem cells. It is highly expressed in mammalian undifferentiated pluripotent cells and known to expand stem cell populations upon up-regulation, whereas the inactivation of YAP1 generates more differentiated progeny [@B35]. YAP1 is also involved in the tumorigenesis of mesothelioma by improving the proliferative capacity of the cancer cells [@B36]. Hypermethylation in the 3\' UTR region and the down-regulation of YAP1 observed in the present study may indicate that YAP1 promotes the differentiation of CSCs, recapitulating the heterogeneity of HMM cells. Methylation in the terminal exon of YAP1 is related to RNA stability and subcellular localization as well as translation regulation [@B37], which warrants further studies.

Aberrant methylation of CpG islands is closely associated with the disturbances of gene expression that result in the transformation of normal mesothelium [@B30]. Thus, attention has focused on the aberrant methylation of CpG islands in the promoter. The present study revealed 4 genes with differential methylation in the CpG islands of promoters in SP cells compared to NSP cells. These genes include hypermethylated basonuclin 1 (BNC1), ribosomal protein S6 kinase (90 kDa), polypeptide 3 (RPS6KA3), twisted gastrulation bone morphogenetic protein (BMP) signaling modulator 1 (TWSG1), and hypomethylated dual specificity phosphatases 15 (DUSP15).

BNC1 is a transcription factor that participates in the mitosis of actively dividing keratinocytes and germ cells of the testis and ovary [@B38]. Previous studies have revealed that it is commonly hypermethylated and silenced in many human malignancies, including solid tumors and hematopoietic neoplasms [@B39], [@B40], implicating its potential role as a tumor suppressor. Similarly, promoter hypermethylation of RPS6KA3 may cause a decrease in cell division. Hsu et al. [@B41] reported that RPS6KA3 is an important gene defining CSCs in triple-negative breast cancer, the most heterogeneous subtype of breast cancers. A breast cancer methylome showed that the expression of RPS6KA3 was regulated via the hypermethylation of CpG islands [@B42]. These previous studies indicate that the hypermethylation of BNC1 and RPS6KA3 could be potentially associated with the quiescent status of CSCs and the heterogeneity of cancer cells. As an inherent feature of CSCs, slowly growing or quiescent stem cell populations in cancer are primarily attributable to the resistance to chemotherapy [@B43]. Thus, the perturbed hypermethylation and consequent inactivation of BNC1 and RPS6KA3 may be a key strategy for putative CSCs to repopulate tumor cell progenies and promote the heterogeneity of HMM; however, the suggested biological functions of these genes require further study. On the other hand, TWSG1, a secreted cysteine-rich protein that regulates the extracellular cell-to-cell BMP signaling involved in normal embryogenesis [@B44], is required for myoepithelial differentiation during the postnatal development of the mammary gland, and its dysregulation induces apoptotic defects, leading to ductal proliferation [@B45]. In human blood leukocytes, exposure to environmental contaminants increases the systemic DNA methylation level in 92 genes, including TWSG1 [@B46]. When cancer cells are exposed to hostile microenvironments, DUSP15 is related to aberrant methylation \[4747, 48\]. Although the precise roles of DUSP15 and TWSG1 in the response of CSCs to cellular and environmental stresses remains to be determined, the aberrant methylation of CpG islands in their promoter region may promote tumor cell viability or differentiation when exposed to unfavorable conditions, ultimately contributing to tumor heterogeneity in HMM. Further studies may be necessary to investigate the functional correlation of aberrant methylation in the promoter regulatory regions and biological properties of a number of epigenetically regulated genes.

Intratumoral heterogeneity has been studied with different perspectives, including genetic alterations, environmental differences, stochastic processes, cell and tissue plasticity, and the presence or absence of a cellular hierarchy [@B2], [@B9], [@B10]. Previous investigations about epigenetic mechanisms in HMM were limited by the lack of a genome-wide assay in DNA methylation profiles and focused on methylation profile in the CpG islands of selected genes. To the best of our knowledge, for the first time, the present study demonstrated the epigenetic heterogeneity of cancer cells using an integrated analysis of the DNA methylome and transcriptome. In the future, these findings may promote the development of novel diagnostic and therapeutic measures for cancers, including HMMs.
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![**Identification of side population (SP) phenotypes in the MS1 cell line.**(A) Side population assay revealed that the MS1 cell line contained a distinct region of SP cells indicated by a trapezoid on each panel. (B) Note the reduced fraction of SP cells with treatment with verapamil.](jcav07p1668g001){#F1}

![**Distribution of MeDIP-seq reads with the DNA methylation pattern in CpG islands and the coding gene region.** (A) Circle plot showing chromosomal locations of Medip-seq reads obtained by NGS for SP and NSP cells. The outside circle depicts the chromosome ideogram in a clockwise rotation. The next track contains red and green colors, indicating genome-wide methylated regions in SP cells and NSP cells, respectively. The height of the histogram bins indicates the density of methylated regions. The innermost circle includes the differentially methylated regions indicated by log~2~ values between MeDIP-seq reads of SP cells. (B) Proportion of MeDIP-seq reads in SP and NSP cells. The x-axis indicates different genome regions. For each region, the normalized number of reads was calculated. The y-axis indicates the proportion of reads in a specific gene element. (C) The DNA methylation level of SP cells was particularly higher than that of NSP cells in CpG islands. (D) SP cells showed a generally increased level of DNA methylation in gene flanking and intragenic regions than that of NSP cells.](jcav07p1668g002){#F2}

![**Validation of MeDIP-seq data using methylation-specific PCR (MSP).**(A) Relative gene expression level of DMGs. The DMGs in NSP cells were used as a reference for the up- or down-regulation of DNA methylation in the SP fraction. (B) DNA methylation patterns of four selected DMGs.](jcav07p1668g003){#F3}

![**Validation of RNA-seq data using quantitative real-time PCR.**(A) Correlation in the expression of differentially regulated genes between RNA-seq and real-time RT-PCR. Log~2~ values were calculated by comparing read counts in SP cells to NSP cells. RT-PCR results showed general consistency with RNA-seq data. (B) Relative mRNA level of differentially up or down-regulated genes found by RNA-seq. GAPDH was used as the housekeeping gene. Relative gene expression was generated according to the 2^-Δ\ ΔCt^ method. \*p-value \<0.05, \*\*p-value \<0.01; Student\'s t-test.](jcav07p1668g004){#F4}

![**Integrated analysis of MeDIP-seq and RNA-seq data.**(A) Venn diagram of DEGs and DMGs. Each group was divided into up-regulated and down-regulated subgroups. The number of genes is given in the middle of each figure section. (B) Bidirectional expression patterns of differentially hypermethylated genes with various genomic elements. (C) Differentially hypomethylated genes with various genomic elements. The number of genes is given at the top of each graph bar.](jcav07p1668g005){#F5}

###### 

Differentially methylated and regulated genes with methylation profiles in CpG islands.

  Gene ID   Chromosome   Genomic context   Methylated region     Fold change (MeDIP-seq)   p-value     Fold change (RNA-seq)   p-value
  --------- ------------ ----------------- --------------------- ------------------------- ----------- ----------------------- ---------
  ATP11A    chr13        Intron            112398122-112400894   2.590                     3.40E-34    -9.298                  0.0105
                         Intron            112503894-112504883   3.263                     8.69E-30                            
  NDST1     chr5         Intron            149895060-149895861   13.727                    1.63E-164   -5.134                  0.04435
                         CDS               149895060-149895861   13.727                    1.63E-164                           
                         CDS               149886968-149888651   2.462                     9.89E-49                            
  MTMR1     chrX         Intron            149681001-149682087   4.667                     2.55E-47    -6.905                  0.02025
                         Intron            149661398-149662354   2.778                     1.21E-19                            
                         CDS               149681001-149682087   4.667                     2.55E-47                            
                         3\'-UTR           149681001-149682087   4.667                     2.55E-47                            
  BNC1      chr15        Upstream 2k       81744675-81745352     2.929                     1.16E-17    -6.420                  0.03335
  EGR3      chr8         CDS               22602725-22605431     4.278                     3.35E-48    -9.350                  0.03775
  TWSG1     chr18        Upstream 2k       9323013-9324201       3.867                     1.62E-33    -6.409                  0.02105
                         Intron            9352211-9352680       2.739                     5.38E-24                            
  ZDHHC20   chr13        Intron            20849079-20850389     9.308                     1.26E-117   -5.174                  0.03855
                         Intron            20876367-20877118     2.238                     9.14E-13                            
  RPS6KA3   chrX         Upstream 2k       20195426-20197844     2.115                     4.33E-13    -7.811                  0.0116
  ZZEF1     chr17        Intron            3906929-3908389       2.139                     5.17E-35    -4.842                  0.04695
                         Downstream 2k     3852723-3855666       2.055                     9.06E-24                            
                         CDS               3906929-3908389       2.139                     5.17E-35                            
  DUSP15    chr20        Upstream2k        29922261-29922719     0.426                     3.524E-26   21.024                  0.0438

The methylation and expression statuses of the NSP samples were utilized as references for those in the SP samples.
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